dual glp-1/gip agonist Free Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 glp 1 and gip glp

doi:10.3389/fcimb.2022.978643 118

In a study published in May, researchers used a large patient dataset to compare the NAION rate within 1 year of adults with Type 2 diabetes starting GLP-1 treatment (like Ozempic) versus those starting dipeptidyl peptidase 4 inhibitors

A simpler protocol with 80% effectiveness that you follow consistently will always outperform a complex protocol with 100% theoretical effectiveness that you abandon after two months

A once-weekly formulation of exenatide has been developed by Amylin Pharmaceuticals and has been marketed by AstraZeneca since 2012 under the trade name Bydureon

Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Trial 8 [Peptide Innovation for Early Diabetes Treatment (PIONEER 6), NCT02692716] was a multi-center, multi-national, placebo-controlled, double-blind trial

however, losing weight (and maintaining weight loss) through diet and exercise alone is challenging